"We are conducting a review of the U.S. Department of Treasury's Notice. We won't speculate on any potential impact until the review is completed," Pfizer spokeswoman Joan Campion said in an emailed statement.

. (Reporting by Lindsay Dunsmuir; Editing by Sandra Maler)

The Treasury's actions, announced earlier on Monday, is the latest to target such deals. In the largest inversion transaction ever, Dublin-based Allergan Plc has agreed to be bought by New York's Pfizer Inc